Market Currents
Roth Capital downgrades Keryx Biopharmaceuticals (KERX -66.4%) to Neutral from Buy after the...
-
Monday, April 2, 2012, 11:11 AM ETRoth Capital downgrades Keryx Biopharmaceuticals (KERX -66.4%) to Neutral from Buy after the firm bombed with Phase 3 testing of its perifosine colon cancer drug. Analysts with the Roth take their price target on KERX down to $4 from $10 - which still stands well-above the current trading price of $1.67.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
